Find Clinical Trial

An open-label, randomised, phase III study comparing trifluridine/tipiracil in combination with bevacizumab to trifluridine/tipiracil monotherapy in patients with refractory metastatic colorectal cancer


← Back
Study Phase

Phase 3

Therapeutic Area

Cancers

IndicationRefractory metastatic colorectal cancer, Solid tumors
SponsorInstitut de Recherches Internationales Servier (I.R.I.S.)
Active substance/
Medical device

TIPIRACIL, TRIFLURIDINE,
S095005

Active Substance CodeS095005
Protocol CodeCL3-95005-007
EudraCT Code2020-001976-14
NCT CodeNCT04737187




Documents and links

Results are not yet available.




Servier Glossary of Terms

To ease the reading, we are developing a glossary of terms. In this glossary, we provide the lay terms used in our lay summaries and the corresponding medical terms. You will find the Servier Glossary of Terms on this link.



© 2021 LES LABORATOIRES SERVIER, an incorporated company of Servier.
All Rights Reserved. Servier does not sell its products over the Internet.
Accessibility